This page summarises, in neutral and accessible language, the main categories of investigational therapies being studied in MPS I-H and related conditions, and explains how they might complement – not replace – current standard of care in the future.
Different problems may need different tools
Even with HSCT and ERT, many children and adults with Hurler syndrome live with:
- Residual brain and neurocognitive involvement
- Progressive skeletal and joint disease
- Valve, airway and respiratory complications
- Lifelong treatment burden (transplant risk, regular infusions)
No single therapy is likely to solve all of these challenges. Researchers are therefore exploring:
- Ways to enhance or refine existing treatments
- New ways to reach hard-to-treat tissues (brain, bone, cartilage)
- Approaches that may reduce long-term burden on families and health systems
Systemic gene therapy is one part of this landscape; the sections below highlight other important directions.
Improving transplant strategies and gene-modified cells
HSCT is already the cornerstone of care for many children with MPS I-H. Research is focusing on how to:
Reduce transplant toxicity
- –Refining conditioning regimens to lower short-term risk while maintaining engraftment.
- –Better supportive care protocols to prevent complicati
Improve donor cell function
- –Investigating alternative stem cell sources (for example cord blood) and optimised graft selection.
- –Exploring ways to increase enzyme production from engrafted cells.
Gene-modified haematopoietic stem cells (HSC gene therapy)
Ex vivo modification of a patient’s own stem cells to overexpress IDUA, followed by reinfusion after conditioning.
These approaches still require conditioning and transplant expertise, but may increase CNS and systemic benefit compared with conventional HSCT alone.
Beyond standard intravenous ERT
Standard ERT improves many somatic features but has limited effect on brain and bone. Investigational strategies include:
Modified or long-acting ERT
Enhanced tissue penetration
Intrathecal or intracerebroventricular ERT
These strategies remain experimental and typically require specialised centres and careful safety monitoring.
Targeting the brain more directly
Because neurocognitive decline is a key feature of untreated Hurler syndrome, several approaches are being investigated to improve CNS outcomes:
Intrathecal or intracisternal gene therapy
Vectors delivered into the CSF to increase local enzyme production within the brain and spinal cord.
Brain-penetrant viral vectors
Systemically or regionally administered vectors designed to cross the blood–brain barrier more effectively.
Receptor-mediated transport systems
Use of ligands that bind to receptors (for example at the blood–brain barrier) to ferry enzymes, RNA or gene vectors into the CNS.
These strategies aim to complement systemic correction by specifically addressing brain involvement, but require intensive safety evaluation.
Repairing the IDUA gene at its source
Beyond adding a working copy of IDUA, some research focuses on:
Genome editing tools (for example CRISPR-based platforms)
Designed to correct or disrupt specific sequences in the genome. For MPS I-H, the concept is to repair or replace faulty IDUA sequences in relevant cells.
Base and prime editing
More precise editing technologies that aim to change a single or small number of DNA bases without inducing large double-strand breaks.
These approaches are at an earlier stage than most gene-addition strategies and raise particular questions about:
- Off-target effects and long-term safety
At present, genome editing in MPS I-H is an area of active laboratory research rather than clinical practice.
Non-genetic approaches to modify storage
Another investigational direction involves small molecule therapies that may:
Reduce substrate production
Substrate reduction therapy (SRT) aims to partially decrease synthesis of GAGs so that residual enzyme activity can keep up better with degradation.
Further detail from the source pages
Further detail6 sections
Act as pharmacological chaperones
Small molecules that stabilise misfolded alpha-L-iduronidase variants, increasing their activity in patients with certain missense mutations.
Influence downstream pathways
Agents that target inflammation, fibrosis, or other secondary pathways activated by lysosomal storage.
These therapies might be used alone in milder forms of MPS I or – more likely for Hurler syndrome – in combination with HSCT, ERT or gene therapy to fine-tune disease control.
Improving outcomes even without new "core" treatments
Not all investigational work is about replacing HSCT or ERT. Other important areas include:
Advanced imaging and biomarkers
- New MRI, CT and echocardiographic techniques for early detection of disease progression.
- Biomarkers to track skeletal, cardiac or CNS involvement more precisely.
Targeted orthopaedic and cardiac strategies
- Improved surgical techniques and perioperative protocols tailored to MPS I-H anatomy and risk.
Digital health and care pathways
- Tools to track mobility, sleep, pain and quality of life in real time.
- Models to streamline multidisciplinary care, transition to adult services and integration with registries
Although these do not change the underlying enzyme defect, they can significantly improve lived experience and long-term outcomes.
Further detail — part 26 sections
Combination and sequencing rather than "either/or"
In practice, future care for Hurler syndrome is likely to involve combinations of approaches rather than a single “winner”. For example:
- HSCT plus CNS-directed gene therapy or ERT
- Systemic gene therapy plus skeletal-focused interventions
- Small molecules used as adjuncts to transplant or gene therapy
Key ideas:
For families and clinicians, this means conversations will continue to evolve as evidence accumulates.
Evaluating investigational options
When reviewing any investigational therapy in MPS I-H, it is helpful to ask:
This structured view helps distinguish promising, evidence-led innovation from approaches that are not yet ready for clinical use.
Making sense of research news
Families often hear about new treatments through news reports or social media long before they are available. It may help to remember:
Your specialist team can help you understand:
- What stage a particular approach is at
- Whether a clinical trial is realistic or appropriate for your situation
- How investigational therapies compare with the care your child or you are already receiving
You are always entitled to ask questions and to take time before deciding whether to consider a trial.
Key points about other investigational approaches
- Multiple investigational strategies are being explored in Hurler syndrome, including optimised HSCT, next-generation ERT, CNS-directed delivery, genome editing, small molecules and organ-focused innovations.
- These approaches aim to address persistent unmet needs – especially brain, bone, cardiac and quality of life outcomes – rather than simply duplicating existing treatments.
- Most are at early or intermediate stages of development and are not available as standard treatments; access is typically through clinical trials.
- Future care is likely to involve combinations and sequencing of therapies rather than a single universal solution.
- Families, clinicians and researchers all benefit from a clear, balanced understanding of what each investigational approach can realistically offer and what remains unknown.
Research hub
Main research themes in Hurler syndrome
Further detail — part 35 sections
Rationale for gene therapy
Why systemic gene therapy is being explored in MPS I-H
Preclinical gene therapy programme
Plain language summary of systemic gene therapy studies
Unmet need
Residual morbidity and quality of life after HSCT/ERT
Current standard of care
HSCT, ERT and multidisciplinary management
Clinical trials and research
Understanding and considering participation in studies